Alfacell Drug Designated Orphan Product
Posted on: Tuesday, 30 January 2007, 15:01 CST
Alfacell Corporation has said that the FDA has granted orphan-drug for its lead drug candidate, Onconase for treatment of malignant mesothelioma.
Alfacell is evaluating Onconase in a confirmatory phase IIIb clinical trial in unresectable malignant mesothelioma.
Orphan drug designation permits Alfacell to be awarded seven years of marketing exclusivity for Onconase for the malignant mesothelioma indication upon FDA approval for this indication.
Other benefits for which Alfacell is eligible with the orphan drug designation include protocol assistance by the FDA in the preparation of a dossier that will meet regulatory requirements; tax credits, research and development grant funding, and reduced filing fees.
Malignant mesothelioma qualifies under orphan drug designation because approximately 4,000 to 5,000 new cases are reported in the US each year.
Source: Datamonitor
Related Articles
- Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
- Paper in Cell Cycle Reports Alfacell's ONCONASE(R) Targets siRNA
- Alfacell's ONCONASE(R) Shows Potential As Radiation Sensitizer for Lung Cancer Treatment
- Alfacell's ONCONASE(R) Shows Promise As Radiation Sensitizer for Lung Cancer Treatment
- Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
- Metabasis Announces European Commission Grants Orphan Medicinal Product Designation to MB07133, Its Product Candidate for the Treatment of Primary Liver Cancer
- Alfacell's Onconase Gets Orphan Drug Nod
- European Commission Grants Orphan Medicinal Product Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for the Prevention of Pulmonary Fungal Infections in Patients Deemed At Risk
- European Commission Grants Orphan Medicinal Product Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
- Oral Drug Cuts Malignant Tumor Size
 |
 |
User Comments (0)
RSS Feeds